ZP5 9676
Alternative Names: ZP5-9676Latest Information Update: 24 Nov 2023
At a glance
- Originator Zero Point Five Therapeutics
- Class Anthelmintics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Helminthiasis
Most Recent Events
- 16 Nov 2023 Preclinical trials in Helminthiasis in USA (PO) prior to November 2023
- 15 Nov 2023 Zero Point Five Therapeutics plans a phase III trial for Soil-Transmitted Helminthiasis (In infants, In children, In adolescents, In adults) in Brazil and Ghana (PO) (NCT06128447)